Patents Assigned to Affimed GMBH
-
Publication number: 20240294647Abstract: The invention relates to multispecific antigen-binding proteins for engaging natural killer (NK) cells for triggering NK cell cytotoxicity by engaging the CD16A (Fc?RIIIA) expressed on NK cells, wherein the antigen-binding protein comprises at least two CD16A antigen-binding moieties and at least a further target antigen-binding moiety. The CD16A antigen-binding moiety comprises light chain and heavy chain variable regions linked one after another in a polypeptide chain and the variable region at the N-terminus of the polypeptide chain comprising the CD16A antigen-binding moiety is a light chain variable region.Type: ApplicationFiled: April 17, 2024Publication date: September 5, 2024Applicant: Affimed GmbHInventors: Michael Tesar, Kristina Ellwanger, Ivica Fucek, Uwe Reusch, Thorsten Ross, Joachim Koch, Erich Rajkovic, Martin Treder
-
Patent number: 11180558Abstract: The invention relates to a multispecific antigen-binding molecule specifically binding to CD16A and consisting of two polypeptide chains, wherein each polypeptide chain comprises at least four variable domains from the N-terminus to the C-terminus in the order: VH_BCMA-VL_CD16A-VH_CD16A-VL_BCM.Type: GrantFiled: July 23, 2019Date of Patent: November 23, 2021Assignee: Affimed GMBHInventors: Thorsten Ross, Ivica Fucek, Kristina Ellwanger, Michael Weichel, Uwe Reusch, Stefan Knackmuss, Erich Rajkovic, Martin Treder
-
Publication number: 20210253698Abstract: The invention relates to multispecific antigen-binding proteins for engaging natural killer (NK) cells for triggering NK cell cytotoxicity by engaging the CD16A (Fc?RIIIA)expressed on NK cells, wherein the antigen-binding protein comprises at least two CD16A antigen-binding moieties and at least a further target antigen-binding moiety. The CD16A antigen-binding moiety comprises light chain and heavy chain variable regions linked one after another in a polypeptide chain and the variable region at the N-terminus of the polypeptide chain comprising the CD16A antigen-binding moiety is a light chain variable region.Type: ApplicationFiled: April 20, 2021Publication date: August 19, 2021Applicant: Affimed GmbHInventors: Michael Tesar, Kristina Ellwanger, Ivica Fucek, Uwe Reusch, Thorsten Ross, Joachim Koch, Erich Rajkovic, Martin Treder
-
Patent number: 11001633Abstract: The invention relates to multispecific antigen-binding proteins for engaging natural killer (NK) cells for triggering NK cell cytotoxicity by engaging the CD16A (Fc?RIIIA) expressed on NK cells, wherein the antigen-binding protein comprises at least two CD16A antigen-binding moieties and at least a further target antigen-binding moiety. The CD16A antigen-binding moiety comprises light chain and heavy chain variable regions linked one after another in a polypeptide chain and the variable region at the N-terminus of the polypeptide chain comprising the CD16A antigen-binding moiety is a light chain variable region.Type: GrantFiled: December 13, 2019Date of Patent: May 11, 2021Assignee: Affimed GmbHInventors: Michael Tesar, Kristina Ellwanger, Ivica Fucek, Uwe Reusch, Thorsten Ross, Joachim Koch, Erich Rajkovic, Martin Treder
-
Publication number: 20200109202Abstract: The invention relates to multispecific antigen-binding proteins for engaging natural killer (NK) cells for triggering NK cell cytotoxicity by engaging the CD16A (Fc?RIIIA)expressed on NK cells, wherein the antigen-binding protein comprises at least two CD16A antigen-binding moieties and at least a further target antigen-binding moiety. The CD16A antigen-binding moiety comprises light chain and heavy chain variable regions linked one after another in a polypeptide chain and the variable region at the N-terminus of the polypeptide chain comprising the CD16A antigen-binding moiety is a light chain variable region.Type: ApplicationFiled: December 13, 2019Publication date: April 9, 2020Applicant: Affimed GmbHInventors: Michael Tesar, Kristina Ellwanger, Ivica Fucek, Uwe Reusch, Thorsten Ross, Joachim Koch, Erich Rajkovic, Martin Treder
-
Patent number: 9701750Abstract: The present invention relates to binding molecules that specifically bind to the human Fc gamma receptor expressed on the surface of natural killer (NK) cells and macrophages (i.e. Fc?RIIIA), and in particular binding molecules that specifically bind the A form Fc?RIII but do not bind to the B form of Fc?RIII, as well as to the use of such binding molecules in the diagnosis and treatment of disease. The invention further extends to polynucleotides encoding such binding molecules, host cells comprising such polynucleotides and methods of producing binding molecules of the invention using such host cells.Type: GrantFiled: April 20, 2015Date of Patent: July 11, 2017Assignee: Affimed GmbHInventors: Karin Hoffmann, Sergey Kipriyanov, Stefan Knackmuss, Fabrice Le Gall, Melvyn Little, Uwe Reusch
-
Patent number: 9035026Abstract: The present invention relates to binding molecules that specifically bind to the human Fc gamma receptor expressed on the surface of natural killer (NK) cells and macrophages (i.e. Fc?RIIIA), and in particular binding molecules that specifically bind the A form Fc?RIII but do not bind to the B form of Fc?RIII, as well as to the use of such binding molecules in the diagnosis and treatment of disease. The invention further extends to polynucleotides encoding such binding molecules, host cells comprising such polynucleotides and methods of producing binding molecules of the invention using such host cells.Type: GrantFiled: May 26, 2006Date of Patent: May 19, 2015Assignee: Affimed GMBHInventors: Karin Hoffmann, Sergey Kipriyanov, Stefan Knackmuss, Fabrice Le Gall, Melvyn Little, Uwe Reusch